Meeting
2017 ASCO Annual Meeting
Frontline hyper-CVAD plus ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Updated results of a phase II study.
Authors
Nicholas James Short
Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Nicholas James Short , Hagop M. Kantarjian , Farhad Ravandi , Naval Guastad Daver , Naveen Pemmaraju , Deborah A. Thomas , Musa Yilmaz , Tapan M. Kadia , Koji Sasaki , Rebecca Garris , Guillermo Garcia-Manero , Courtney Denton Dinardo , Marina Konopleva , Zeev Estrov , Nitin Jain , William G. Wierda , Vicky Jeanis , Jorge E. Cortes , Susan Mary O'Brien , Elias Jabbour
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT01424982
Citation
J Clin Oncol 35, 2017 (suppl; abstr 7013)
DOI
10.1200/JCO.2017.35.15_suppl.7013
Abstract #
7013
Poster Bd #
213
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Updated results from phase II study of combination of hyper-CVAD (HCVAD) with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
First Author: Koji Sasaki
Poster
2023 ASCO Annual Meeting
Final analysis of the phase IB part of the LOC-R01 trial, a non-comparative randomized phase IB/II study of escalating doses of lenalidomide and ibrutinib in association with R-MPV for patients with a newly diagnosed primary central nervous system lymphoma (PCNSL).
First Author: Marion Alcantara
Poster
2022 ASCO Annual Meeting
A phase II study of hyper-CVAD with sequential blinatumomab (Blina), with or without inotuzumab ozogamicin (INO), in adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL).
First Author: Nicholas James Short
Poster
2018 ASCO Annual Meeting
A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+ acute lymphoblastic leukemia (ALL): Updated results.
First Author: Abdul Hamid Bazarbachi